Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT | BSE: 524742 | ISIN: INE475E01026 | Industry: Pharmaceuticals
| Falling Comet
1610.5000 41.40 (2.64%)
NSE Apr 07, 2026 15:31 PM
Volume: 132.0K
 

1610.50
2.64%
ICICI Securities Limited
The Q3FY21 operational performance was mostly in line with our expectations whereas profitability was below due to lower than expected other income. Revenues grew 20.2% YoY to | 274 crore. EBITDA margins improved 89 bps YoY to 30.6% due to higher gross margins, lower other expenses partly offset by higher staff costs likely due to acquired subsidiaries. Hence, EBITDA grew 23.9% YoY to | 84 crore. However, PAT...
Number of FII/FPI investors decreased from 190 to 174 in Dec 2025 qtr
More from Caplin Point Laboratories Ltd.
Recommended